Biotek-snakken — Maj 2021
-
Video: Tæt på Scandion Oncology, Ascelia Pharma & Hansa.: https://www.proinvestor.com/index.php?p=debat_1&postid=93476
-
-
HRTX: Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF
(HTX-011) for the Management of Postoperative Pain for up to 72 Hours https://ir.herontx.com/news-releases/news-release-details/heron-therapeutics-announces-us-fda-approval-zynreleftm-htx-011 -
- ZYNRELEF is the first and only FDA-approved extended-release dual-acting local anesthetic, clinically proven to manage pain and to eliminate the need for opioids for up to 72 hours following surgery better than bupivacaine solution, the current standard-of-care -
- Full U.S. commercial launch of ZYNRELEF is planned for July 2021 -
-
HRTX seneste investor præsentation efter dagens godkendelse https://ir.herontx.com/static-files/f9523204-77d9-4129-b590-73dcb00476d2
-
Udover Q&A mandag med Genmab har Proinvestor sammen med Nordnet
biotekwebinar med Genmab, Bavarian og Zealand Pharma tirsdag. Tlmelding: https://events.nordnet.dk/nordnet-events/kom-helt-taet-paa-tre-biotekvirksomheder-bavarian-zealand-pharma-genmab/ -
Cantargia: Intervju med vd Göran Forsberg (video)
FilmprojektorRedeye har talat med Göran Forsberg, Vd på Cantargia, om nya indikationer för CAN04 på cancerområdet och om de lovande prekliniska resultaten för CAN10. https://www.redeye.se/research/811901/cantargia-intervju-med-vd-goran-forsberg-video-6
-
Orphazyme, Saniona og Cellectar med på Oppenheimer Rare and Orphan Disease Summit 021.05. https://www.oppenheimer.com/events/2021/rare-orphan-disease-summit.aspx
-
Servicemeddelelse. Efter lang tids analyse, gennemgang og omkodning i et 12 år gammelt maskinrum tror vi, at uploadsproblemet i debatten er tæt på en løsning.
Kør endelig løs og meld tilbage ved evt. fejl. -
XBRANE ANNOUNCES AMBITION TO GENERATE POSITIVE OPERATING CASH FLOW MONTHLY BY LATE 2023/EARLY 2024 AND TO INITIATE ONE NEW BIOSIMILAR DEVELOPMENT PROGRAM PER ANNUM.
https://xbrane.com/en/mfn_news/xbrane-announces-ambition-to-generate-positive-operating-cash-flow-monthly-by-late-2023-early-2024-and-to-initiate-one-new-biosimilar-development-program-per-annum/ -
Capital Markets Day
Xbrane will host a virtual capital markets day for investors, analysts and journalists tomorrow on May 17, 2021, 14.00-15.30 CET. -
Det kører på skinner, så må vi bare ignorere volatiliteten og holde den LANGSIGTET....ihvertfald
kæmpe potentiale -
Der hvor jeg ser den store fordel for Xbrane, er at det er meget hurtigere, mindre risikabelt, og meget billigere at få nye produkter på markedet....Den kan blive guld værd på 3-5 års sigt, hvis tingene flasker sig.
-
Alm. Biotek aktier er meget mere risikable.
-
God præsentation som viser lidt om risk
/reward i XBrane....https://tv.streamfabriken.com/2021-02-24-xbrane-biopharma?seek=740
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind